Tuesday - July 1, 2025
Single Infusion of CARVYKTI (ciltacabtagene Autoleucel) Delivered Lasting Treatment-Free Remissions for at Least Five Years in Patients With Relapsed or Refractory Multiple Myeloma
June 04, 2025
RARITAN, New Jersey, June 4 -- Johnson and Johnson Innovative Medicine (formerly the Janssen Pharmaceutical Companies of Johnson and Johnson) issued the following news release:

* * *

Single infusion of CARVYKTI (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma

New long-term CARTITUDE-1 data show one-third of patients treated with CARVYKTI remain progressio . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products